Celecoxib Improves DFS, OS in ctDNA-Positive Colon Cancer
Celecoxib plus chemo can improve outcomes over placebo plus chemo in patients with colon cancer who have ctDNA-positive plasma after surgery.
Celecoxib plus chemo can improve outcomes over placebo plus chemo in patients with colon cancer who have ctDNA-positive plasma after surgery.
Three case studies exploring complexities of diagnosing, treating, and managing patients with various complement-mediated kidney disorders.
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
Jointly organized by the EHA and EBMT, the 7th European CAR T-cell Meeting is taking place on February 6-8, 2025, in Strasbourg, France, and online,…
Radiation plus immunotherapy may help some patients with invasive bladder cancer keep their bladders, according to a study published in Clinical Cancer Research.
Late on Friday, Feb. 7, the Trump administration announced that indirect costs paid on grants to U.S. medical research institutions would—starting immediately—henceforth be capped at…
Individuals with unhealthy lifestyles may derive the most benefit from aspirin for colorectal cancer prevention, according to results of a prospective cohort study.Regular aspirin use…
Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers…
This study evaluated the efficacy and safety of pegylated liposomal doxorubicin for patients with partially platinum-sensitive, platinum-resistant, or plat
Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.
Oxford University Press (OUP) invites applications for the position of Deputy Editor for The Oncologist. There are two Deputy Editor positions available, each